ABBV analyst estimates
AbbVie (ABBV) analyst ratings, the average price target and its range, and every firm's latest call.
- 25 firms rate ABBV: 21 buy, 4 hold, 0 sell.
- The average price target is $316.87 from None analysts, from $275.00 to $349.00.
ABBV analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Nov 18, 2026 | Piper Sandler | Abbvie (ABBV) PT Raised to $349 at Piper Sandler | $349.00 |
| Nov 4, 2026 | BMO Capital | Abbvie (ABBV) PT Raised to $315 at Freedom Broker | $315.00 |
| Nov 2, 2026 | UBS | Abbvie (ABBV) PT Raised to $295 at UBS | $295.00 |
| Nov 2, 2026 | Wells Fargo | Abbvie (ABBV) PT Raised to $340 at Wells Fargo | $340.00 |
| Nov 2, 2026 | Canaccord Genuity | Abbvie (ABBV) PT Raised to $338 at Canaccord | $338.00 |
| Nov 2, 2026 | Guggenheim | Abbvie (ABBV) PT Raised to $322 at Guggenheim | $322.00 |
| Nov 2, 2026 | Bernstein | Abbvie (ABBV) PT Raised to $275 at Bernstein SocGen Group | $275.00 |
| Nov 2, 2026 | RBC Capital | Abbvie (ABBV) PT Raised to $330 at RBC Capital; 'Solid Quarter Validates Continued Strong Execution' | $330.00 |
| Nov 2, 2026 | Cantor Fitzgerald | Abbvie (ABBV) PT Raised to $325 at Cantor Fitzgerald | $325.00 |
| Oct 23, 2026 | Goldman Sachs | AbbVie price target raised to $294 from $258 at Goldman Sachs | $294.00 |
| Oct 21, 2026 | Barclays | AbbVie price target raised to $325 from $300 at Barclays | $325.00 |
| Oct 8, 2026 | Cantor Fitzgerald | Abbvie (ABBV) PT Raised to $290 at Cantor Fitzgerald | $290.00 |
| Oct 7, 2026 | Morgan Stanley | AbbVie price target raised to $310 from $296 at Morgan Stanley | $310.00 |
| Oct 6, 2026 | Scotiabank | AbbVie price target raised to $320 from $280 at Scotiabank | $320.00 |
| Sep 10, 2026 | HSBC | AbbVie price target raised to $315 from $300 at HSBC | $315.00 |